India’s major drug makers are shifting from low-margin generic medicine manufacturing to high-value innovation, supported by government schemes like PRIP. While this strategy targets better long-term profits, it requires heavy spending and carries regulatory risks. Investors should monitor how companies balance this expensive research transition with US FDA compliance standards.
The Indian pharmaceutical industry is entering a new phase of its evolution. For decades, the sector has relied on supplying affordable generic medicines to the world. Now, major companies including Sun Pharma, Biocon, and Glenmark are shifting their strategy toward high-value research and development (R&D). This move aims to help these firms create innovative medicines and specialty products, rather than competing only on price and volume in the crowded generics market.
Financial and structural support for this change is increasing. The government’s Promotion of Research and Innovation in Pharma & MedTech (PRIP) scheme has already approved ₹1,600 crore for 41 initial projects. This initiative is designed to encourage private investment, which has already surpassed ₹3,000 crore as companies look to upgrade their infrastructure. For example, Sun Pharma invested ₹3,474.1 crore in R&D during FY2025-26, highlighting the scale of capital required to compete on a global innovation level.
However, this transition to research-led business models comes with significant financial and execution risks. Drug discovery involves long gestation periods and high costs. Currently, Indian firms spend roughly 7-8% of their revenue on R&D, which is significantly lower than the 15-25% spent by global innovators. Closing this gap is essential for success, but it puts immediate pressure on cash flow and profit margins.
Regulatory hurdles remain a critical area for investors to watch. As companies try to enter more complex drug markets, they must meet strict international quality standards. Data integrity issues continue to be a challenge, with approximately 60% of US FDA warning letters involving Indian facilities in FY2025. Failure to meet these requirements can lead to import bans or costly remediation, which can derail the benefits of new product launches.
Moving forward, the success of this pivot will depend on how efficiently companies manage their capital. Investors may want to look beyond revenue growth and focus on the quality of the R&D pipeline. Important monitorables include the success rate of clinical trials, the ability of companies to secure international regulatory approvals without quality-related delays, and whether the return from high-value drugs can eventually offset the high costs of research.